Bliss GVS Pharma Reports Financial Challenges Amid Declining Performance Metrics in March 2025
Bliss GVS Pharma has announced its financial results for the quarter ending March 2025, revealing operational challenges. Key performance metrics, including Profit Before Tax and Profit After Tax, have declined significantly. Additionally, rising interest expenses and a drop in operating profit and margin raise concerns about the company's financial stability and business model sustainability.
Bliss GVS Pharma has recently reported its financial results for the quarter ending March 2025, revealing notable challenges within its operations. The company's score has undergone an adjustment, reflecting a shift in evaluation over the past three months. The financial data indicates a decline in key performance metrics. Profit Before Tax less Other Income (PBT) stands at Rs 11.37 crore, marking a significant year-on-year decrease. Similarly, Profit After Tax (PAT) has also shown a downward trend, recorded at Rs 15.54 crore. The interest expenses have seen a rise, suggesting increased borrowings, which may impact future financial stability.
Operating Profit has reached its lowest point in five quarters at Rs 21.09 crore, with the Operating Profit Margin also declining to 10.65%, indicating challenges in operational efficiency. Furthermore, a substantial portion of the company's income is derived from non-operating activities, raising concerns about the sustainability of its business model.
These developments highlight the current difficulties faced by Bliss GVS Pharma in the competitive pharmaceuticals and drugs industry.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
